nubeqa
bayer s.a. - darolutamida - antiandrÓgenos
nubeqa
bayer ag - darolutamide - prostática benigna neoplasias, a castração-resistente - terapia endócrina - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
creslip
althaia s.a indústria farmacêutica - rosuvastatina cálcica - antilipemicos
crestor
astrazeneca do brasil ltda - rosuvastatina cálcica - antilipemicos
plenance
libbs farmacÊutica ltda - rosuvastatina cálcica - antilipemicos
rosustatin
nova quimica farmacÊutica s/a - rosuvastatina cálcica - antilipemicos
rosuvastatina calcica
aurobindo pharma indÚstria farmacÊutica limitada - rosuvastatina cálcica - antilipemicos
rosuvastatina calcica
ranbaxy farmacÊutica ltda - rosuvastatina cálcica - antilipemicos
rosuvastatina calcica
sandoz do brasil indÚstria farmacÊutica ltda - rosuvastatina cálcica - antilipemicos
rosuvastatina cálcica
sanofi medley farmacÊutica ltda. - rosuvastatina cálcica - antilipemicos